Format

Send to

Choose Destination
Cancers (Basel). 2019 Aug 13;11(8). pii: E1164. doi: 10.3390/cancers11081164.

Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers.

Author information

1
Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
2
Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
3
Rush Precision Oncology Program, Rush University Medical Center, Chicago, IL 60612, USA.
4
Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA. ashiq_masood@rush.edu.
5
Rush Precision Oncology Program, Rush University Medical Center, Chicago, IL 60612, USA. ashiq_masood@rush.edu.

Abstract

Room for improvement exists regarding recommendations for screening, staging, therapy selection, and frequency of surveillance of gastrointestinal cancers. Screening is costly and invasive, improved staging demands increased sensitivity and specificity to better guide therapy selection. Surveillance requires increased sensitivity for earlier detection and precise management of recurrences. Peripherally collected blood-based liquid biopsies enrich and analyze circulating tumor cells and/or somatic genomic material, including circulating tumor DNA along with various subclasses of RNA. Such assays have the potential to impact clinical practice at multiple stages of management in gastrointestinal cancers. This review summarizes current basic and clinical evidence for the utilization of liquid biopsy in cancers of the esophagus, pancreas, stomach, colon, and rectum. Technical aspects of various liquid biopsy methodologies and targets are reviewed and evidence supporting current commercially available assays is examined. Finally, current clinical applicability, potential future uses, and pitfalls of applying liquid biopsy to the screening, staging and therapeutic management of these diseases are discussed.

KEYWORDS:

circulating tumor DNA; circulating tumor cell; gastrointestinal cancer; liquid biopsy

Conflict of interest statement

Ashiq Masood: Bristol Myer Squibb, boehringer ingelheim and Biocept. All other authors declare no conflict of interest.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center